Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gitte Gerhard"'
Autor:
Jean C.Y. Wang, John E. Dick, Cynthia Guidos, Donna E. Hogge, Mark D. Minden, Yulia Merkulova, Sofie Perdu, Stevan Lauriault, Goce Bogdanoski, James A. Kennedy, Gitte Gerhard, Jessica McLeod, Andreea C. Popescu, Nathan Mbong, Amanda Mitchell, Yan Xing, Julie S. Yuan, Weihsu C. Chen
Many promising new cancer drugs proceed through preclinical testing and early-phase trials only to fail in late-stage clinical testing. Thus, improved models that better predict survival outcomes and enable the development of biomarkers are needed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace6912470dc065ae62d296a0ae6d9ee
https://doi.org/10.1158/0008-5472.c.6507614
https://doi.org/10.1158/0008-5472.c.6507614
Autor:
Jean C.Y. Wang, John E. Dick, Cynthia Guidos, Donna E. Hogge, Mark D. Minden, Yulia Merkulova, Sofie Perdu, Stevan Lauriault, Goce Bogdanoski, James A. Kennedy, Gitte Gerhard, Jessica McLeod, Andreea C. Popescu, Nathan Mbong, Amanda Mitchell, Yan Xing, Julie S. Yuan, Weihsu C. Chen
Supplemental Methods Supplemental Table 1 Supplemental Figures 1-6 1. Pretreatment with cytarabine potentiates the effects of FED in AML xenografts. Supplemental Figure 2. PF cytometry analysis of AML samples. Supplemental Figure 3. Immunophenotypic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0407829e704b03b162569a3c7be4cf1c
https://doi.org/10.1158/0008-5472.22408769.v1
https://doi.org/10.1158/0008-5472.22408769.v1
Autor:
Mark D. Minden, Sofie Perdu, Amanda Mitchell, Donna E. Hogge, Yulia Merkulova, Nathan Mbong, John E. Dick, Stevan Lauriault, Yan Xing, Cynthia J. Guidos, Goce Bogdanoski, Gitte Gerhard, Jessica McLeod, Weihsu C. Chen, Jean C.Y. Wang, Julie S. Yuan, James A. Kennedy, Andreea C. Popescu
Publikováno v:
Cancer research. 76(5)
Many promising new cancer drugs proceed through preclinical testing and early-phase trials only to fail in late-stage clinical testing. Thus, improved models that better predict survival outcomes and enable the development of biomarkers are needed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::719c5ceb629b05bda21240b825b2f96a
https://pubmed.ncbi.nlm.nih.gov/26833125
https://pubmed.ncbi.nlm.nih.gov/26833125
Autor:
Mark D. Minden, Marco A. Marra, Cynthia J. Guidos, Wei Zhang, John E. Dick, Donna E. Hogge, Yan Xing, Andreea C. Popescu, Richard A. Moore, Weihsu Claire Chen, Gitte Gerhard, Jean C.Y. Wang, Yussanne Ma, Nathan Mbong, Julie S. Yuan
Publikováno v:
Cancer Research. 74:2914-2914
Research to develop new anti-cancer treatments has recently shifted focus to identifying and targeting molecules and pathways essential for cancer stem cell survival. However, preclinical models that rely on cell lines for drug testing do not capture
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c83a27bcda96b3680d8be2cb13e75c4
https://doi.org/10.1158/1538-7445.am2014-2914
https://doi.org/10.1158/1538-7445.am2014-2914
Autor:
Andreea C. Popescu, John E. Dick, Cynthia J. Guidos, Yan Xing, Julie Yuan, Mark D. Minden, Donna E. Hogge, Gitte Gerhard, Jean Cy Wang, Weihsu C. Chen
Publikováno v:
Cancer Research. 73:907-907
Small molecule inhibitors of Janus kinase 2 (JAK2) such as Ruxolitinib and SAR302503 have demonstrated efficacy in clinical trials for treatment of myeloproliferative disorders. Activated JAK2 signaling has been reported in some acute myeloid leukemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a4f854f2fb79dfb6ee513500d8b1373
https://doi.org/10.1158/1538-7445.am2013-907
https://doi.org/10.1158/1538-7445.am2013-907
Autor:
Jean C.Y. Wang, Julie S. Yuan, Weihsu Claire Chen, Yan Xing, Cynthia J. Guidos, Donna E. Hogge, John E. Dick, Gitte Gerhard, Andreea C. Popescu, Mark D. Minden
Publikováno v:
Blood. 118:3624-3624
Abstract 3624 Small molecule inhibitors targeting somatic mutations of Janus kinase 2 (JAK2) have demonstrated effectiveness in clinical trials for treatment of myeloproliferative disorders. Activated JAK2 signaling has been reported in some acute my
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04bb5a9e20474e942b1c92620df2424e
https://doi.org/10.1182/blood.v118.21.3624.3624
https://doi.org/10.1182/blood.v118.21.3624.3624
Autor:
Natalia Zisman, Wahseng Lim, Donna E. Hogge, Troy Harasym, Gitte Gerhard, Peter Kim, Lawrence D. Mayer
Publikováno v:
Blood. 114:2071-2071
Abstract 2071 Poster Board II-48 Background: Combinations of cytarabine (Ara-C) and daunorubicin (DNR) have been the mainstay of induction chemotherapy for AML for three decades. Although many patients achieve a complete remission (CR), at least 20%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24046c590de36058d6cd97e4249cd682
https://doi.org/10.1182/blood.v114.22.2071.2071
https://doi.org/10.1182/blood.v114.22.2071.2071